BetterLife Pharma Director and Audit Chair Robert Metcalfe Resigns

An announcement from BetterLife Pharma ( (TSE:BETR) ) is now available.

BetterLife Pharma Inc. has announced the resignation of Robert Metcalfe from its board of directors, where he served for six years and chaired the audit committee, marking a notable change in the company’s governance structure. Chief executive Ahmad Doroudian thanked Metcalfe for his long-standing service and said the company will begin searching for new director candidates as it advances its development plans, a move that could influence oversight and strategic direction as the biotech pursues its neurological and antiviral drug pipeline.

Spark’s Take on TSE:BETR Stock

According to Spark, TipRanks’ AI Analyst, TSE:BETR is a Underperform.

BetterLife Pharma is currently in a precarious financial position with no revenue, substantial losses, and a high leverage risk due to negative equity. Technical indicators show a lack of momentum, and the valuation is unattractive due to negative earnings. The overall outlook is negative, reflecting significant financial instability.

To see Spark’s full report on TSE:BETR stock, click here.

More about BetterLife Pharma

BetterLife Pharma Inc. is an emerging biotechnology company focused on developing and commercializing BETR-001, a non-hallucinogenic, non-controlled LSD derivative in preclinical and IND-enabling studies for the treatment of various neurological disorders. The company holds a synthesis patent that helps reduce regulatory hurdles and has a pending patent covering composition and methods of use, potentially extending protection to around 2042, and it also owns a separate drug candidate targeting viral infections for which it is seeking strategic development alternatives.

Average Trading Volume: 123,963

Technical Sentiment Signal: Sell

Current Market Cap: C$7.59M

For an in-depth examination of BETR stock, go to TipRanks’ Overview page.